ArticleGlia2010
Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes.
Article in Glia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 62 citations in OpenAlex.
- The Cell-Specific Effects of the Human Remyelination-Promoting rHIgM22 on Sphingolipid Metabolism in Cultured Glial Cells.Neurochemical research · 2026Article
- Identification of the Lipid Antigens Recognized by rHIgM22, a Remyelination-Promoting Antibody.Neurochemical research · 2023Article
- Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis.International journal of molecular sciences · 2023Review
- The use of patient-specific stem cells in different autoimmune diseases.Saudi journal of biological sciences · 2022Review
- Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis.Clinical and translational science · 2022Article
- Regulatory Cells in Multiple Sclerosis: From Blood to Brain.Biomedicines · 2022Review
- Antidepressant amitriptyline-induced matrix metalloproteinase-9 activation is mediated by Src family tyrosine kinase, which leads to glial cell line-derived neurotrophic factor mRNA expression in rat astroglial cells.Neuropsychopharmacology reports · 2019Article
- Human Remyelination Promoting Antibody Stimulates Astrocytes Proliferation Through Modulation of the Sphingolipid Rheostat in Primary Rat Mixed Glial Cultures.Neurochemical research · 2019Article
- Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases.Frontiers in pharmacology · 2019Review
- Multiple Sclerosis: Mechanisms of Disease and Strategies for Myelin and Axonal Repair.Neurologic clinics · 2018Review
- Silent Free Fall at Disease Onset: A Perspective on Therapeutics for Progressive Multiple Sclerosis.Frontiers in neurology · 2018Review
- Remyelinating Pharmacotherapies in Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Adult oligodendrocyte progenitor cells - Multifaceted regulators of the CNS in health and disease.Brain, behavior, and immunity · 2016Review
- Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease.Molecular neurobiology · 2016Review
- Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis.International journal of physical medicine & rehabilitation · 2016Article
- Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.Expert opinion on biological therapy · 2016Review
- Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders.Journal of neurochemistry · 2015Article
- Review
- Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.Expert review of neurotherapeutics · 2013Review
- Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.Discovery medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeHuman remyelination promoting IgM mAbs target oligodendrocytes (OLs) and function in animal models of multiple sclerosis (MS). However, their mechanism of action is unknown. This study seeks to identify the cellular mechanism of action of a recombinant human IgM on OL survival.
methodsBinding of rHIgM22 to the surface of rat OLs was studied by co-localization with various markers. RHIgM22-mediated effects on apoptotic signaling in OLs, differentiation markers, and signaling molecules were detected by Western blotting and immunoprecipitation.
resultsRHIgM22 co-localized with integrin β3 but not other integrin β-chains in OLs. Downstream of integrin β3 we identified Src family kinase (SFK) Lyn as a key player of rHIgM22-mediated actions in OLs. Lyn immunoprecipitated in a complex together with integrin αvβ3 and PDGFαR. Lyn expression was 9-fold up-regulated and Lyn activation was 3-fold higher inrHIgM22-treated OL cultures compared with controls. RHIgM22 inhibited apoptotic signaling by greater than 10-fold reduction of caspase-3 and capsase-9 cleavage and reduced by 4-fold expression of differentiation markers MBP and MOG in OLs. SFK inhibitors PP2 and SU6656 inhibited Lyn activity and restored caspase-cleavage in OLs. A human IgM that did not promote remyelination and medium wereused as controls.
conclusionsrHIgM22 prevented apoptotic signaling andinhibited OL differentiation by Lyn implying thatIgM-mediated remyelination is due toprotection of OPC and OLs rather than promotion of OPC differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.